Hopfner Robert Lorne — SEC insider filings
SEC reporting owner CIK 1551966. 29 insider filings on record with FilingPulse; latest filed 2026-10-14.
Transaction summary — filings shown
Covers all 29 filings on record, filed 2021-01-08 to 2026-10-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 10 legs across 7 filings — 3,481,620 shares, $20,720,433 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 40 legs across 8 filings — 817,549 shares, $22,042,024 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 36.
- Largest priced transaction: purchase of 576,923 shares @ $13.00 ($7,499,999) in Rallybio Corp, filed 2021-08-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | Director | 9 | — | 40 legs · 817,549 sh · $22,042,024 | 1 |
| Inozyme Pharma, Inc. (INZY) | Director | 10 | 8 legs · 2,903,697 sh · $13,203,084 | — | 6 |
| Rallybio Corp (RLYB) | Director | 8 | 1 leg · 576,923 sh · $7,499,999 | — | 15 |
| Evommune, Inc. (EVMN) | Director, 10% owner | 2 | 1 leg · 1,000 sh · $17,350 | — | 14 |
Insider filings — Hopfner Robert Lorne
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-14 | 4 | Rallybio Corp (RLYB) | Option exercise (M): 9,196 @ $7.60 · Option exercise (M): 3,562 @ $2.38 · Option exercise (M): 2,062 @ $15.28 · Option exercise (M): 9,196 (derivative) @ $0.56 · Option exercise (M): 3,562 (derivative) @ $0 · Option exercise (M): 2,062 (derivative) @ $0 | EDGAR |
| 2025-12-22 | 4 | Evommune, Inc. (EVMN) | Purchase (P): 1,000 @ $17.35 | EDGAR |
| 2025-11-12 | 4 | Evommune, Inc. (EVMN) | Conversion (C): 3,026 · Conversion (C): 1,441,032 · Conversion (C): 1,632,441 · Conversion (C): 294,502 · Conversion (C): 25,790 (derivative) · Conversion (C): 7,145,647 (derivative) · +8 more | EDGAR |
| 2025-07-03 | 4 | Inozyme Pharma, Inc. (INZY) | Code (U): 2,923,110 @ $4 · Code (U): 1,571,741 @ $4 | EDGAR |
| 2025-05-15 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 73,571 (derivative) @ $0.70 | EDGAR |
| 2024-06-20 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2023-08-03 | 4 | Inozyme Pharma, Inc. (INZY) | Purchase (P): 119,048 @ $4.80 · Purchase (P): 714,285 @ $4.80 | EDGAR |
| 2023-06-15 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 15,490 (derivative) @ $0 | EDGAR |
| 2023-05-15 | 4 | Inozyme Pharma, Inc. (INZY) | Purchase (P): 219,230 @ $6.48 · Purchase (P): 228,702 @ $6.25 | EDGAR |
| 2023-03-30 | 4 | Inozyme Pharma, Inc. (INZY) | Purchase (P): 344,592 @ $4.54 | EDGAR |
| 2023-03-29 | 4 | Inozyme Pharma, Inc. (INZY) | Purchase (P): 51,074 @ $3.70 · Purchase (P): 156,766 @ $4.16 | EDGAR |
| 2022-06-14 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 9,367 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 13,440 (derivative) @ $0 | EDGAR |
| 2022-04-20 | 4 | Inozyme Pharma, Inc. (INZY) | Purchase (P): 1,070,000 @ $3.69 | EDGAR |
| 2022-01-05 | 4 | Rallybio Corp (RLYB) | Grant/award (A): 6,242 (derivative) @ $0 | EDGAR |
| 2021-08-04 | 4 | Rallybio Corp (RLYB) | Other (J): 1,694,388 · Purchase (P): 576,923 @ $13 · Other (J): 10,789,193 (derivative) · Grant/award (A): 13,440 (derivative) @ $0 | EDGAR |
| 2021-06-24 | 4 | Inozyme Pharma, Inc. (INZY) | Grant/award (A): 9,367 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | Vaxcyte, Inc. (PCVX) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-02-10 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 50,874 @ $25.64 · Sale (S): 28,922 @ $26.06 · Sale (S): 38,248 @ $27.12 · Sale (S): 88,756 @ $28.07 · Sale (S): 93,740 @ $28.75 · Sale (S): 37,271 @ $25.75 · +3 more | EDGAR |
| 2021-02-04 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 14,234 @ $25.13 · Sale (S): 2,768 @ $25.06 | EDGAR |
| 2021-02-02 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 2,000 @ $25.07 | EDGAR |
| 2021-01-27 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 19,511 @ $25.61 · Sale (S): 15,461 @ $26.07 · Sale (S): 16,769 @ $25.23 · Sale (S): 1,373 @ $26.13 · Sale (S): 2,140 @ $25.30 | EDGAR |
| 2021-01-22 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 19,046 @ $25.35 · Sale (S): 100 @ $25.11 · Sale (S): 11,383 @ $25.16 | EDGAR |
| 2021-01-19 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 14,918 @ $25.88 · Sale (S): 22,869 @ $25.74 · Sale (S): 3,808 @ $26.05 · Sale (S): 42,516 @ $25.55 · Sale (S): 7,000 @ $26.05 | EDGAR |
| 2021-01-13 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 12,480 @ $25.42 · Sale (S): 24,980 @ $26.69 · Sale (S): 12,206 @ $27.02 · Sale (S): 17,666 @ $26.35 · Sale (S): 901 @ $27.05 · Sale (S): 26,010 @ $25.90 · +1 more | EDGAR |
| 2021-01-08 | 4 | Vaxcyte, Inc. (PCVX) | Sale (S): 34,913 @ $29.24 · Sale (S): 22,507 @ $29.99 · Sale (S): 24,524 @ $27.75 · Sale (S): 22,587 @ $28.80 · Sale (S): 469 @ $29.51 · Sale (S): 31,468 @ $26.43 · +2 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-06 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1551966 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs